neostigmine has been researched along with Recrudescence in 11 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with acute colonic pseudo-obstruction who have not had a response to conservative therapy, treatment with neostigmine rapidly decompresses the colon." | 9.09 | Neostigmine for the treatment of acute colonic pseudo-obstruction. ( Kimmey, MB; Ponec, RJ; Saunders, MD, 1999) |
| "In patients with acute colonic pseudo-obstruction who have not had a response to conservative therapy, treatment with neostigmine rapidly decompresses the colon." | 5.09 | Neostigmine for the treatment of acute colonic pseudo-obstruction. ( Kimmey, MB; Ponec, RJ; Saunders, MD, 1999) |
| "Administration of PEG in patients with Ogilvie's syndrome after initial resolution of colonic dilation may increase the sustained response rate after initial therapeutic intervention." | 2.72 | Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial. ( Avgerinos, A; Bergele, C; Mantides, A; Nastos, H; Sgouros, SN; Stefanidis, G; Vassiliadis, K; Vlachogiannakos, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cachemaille, M | 1 |
| Olofsson, M | 1 |
| Livio, F | 1 |
| Pascale, P | 1 |
| Zingg, T | 1 |
| Boegli, Y | 1 |
| Yang, ZX | 1 |
| Xiong, H | 1 |
| Zhang, YH | 1 |
| Bao, XH | 1 |
| Jiang, YW | 1 |
| Wu, Y | 1 |
| Wang, S | 1 |
| Chang, XZ | 1 |
| Qin, J | 1 |
| Lin, Q | 1 |
| Wu, XR | 1 |
| Sgouros, SN | 1 |
| Vlachogiannakos, J | 1 |
| Vassiliadis, K | 1 |
| Bergele, C | 1 |
| Stefanidis, G | 1 |
| Nastos, H | 1 |
| Avgerinos, A | 1 |
| Mantides, A | 1 |
| Litman, RS | 1 |
| Younan, MM | 1 |
| Patt, RB | 1 |
| Ward, DS | 1 |
| Tsimmerman, IaS | 1 |
| Zueva, ED | 1 |
| Ponec, RJ | 1 |
| Saunders, MD | 1 |
| Kimmey, MB | 1 |
| Breccia, M | 1 |
| Girmenia, C | 1 |
| Mecarocci, S | 1 |
| Cartoni, C | 1 |
| Carmosino, I | 1 |
| Tafuri, A | 1 |
| Alimena, G | 1 |
| Lee, C | 1 |
| Mok, MS | 1 |
| Barnes, A | 1 |
| Katz, RL | 1 |
| Oberklaid, F | 1 |
| Hopkins, IJ | 1 |
| Buntain, WL | 1 |
| Buonocore, E | 1 |
| Royal, SA | 1 |
| MacKechnie, HL | 1 |
| Squires, AH | 1 |
| Platts, M | 1 |
| Pruzanski, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Safety and Efficacy of Different Routes of Neostigmine Administration for Acute Colonic Pseudo Obstruction: a Prospective Randomized Trial[NCT04951726] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-02-04 | Recruiting | ||
| A New Approach of Neostigmine in Unavoidable Post Operative Ileus After Surgery[NCT00676377] | Phase 4 | 3 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension[NCT02543658] | Phase 2 | 80 participants (Actual) | Interventional | 2015-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Days in hospital within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 20 |
| Conservative Treatment | 19 |
Days in ICU within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | days (Median) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 12 |
Death during from randomization to 90 days after onset. (NCT02543658)
Timeframe: From randomization to 90 days after onset.
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 10 |
| Conservative Treatment | 11 |
Medical expenses within 6 months after randomisation (NCT02543658)
Timeframe: From randomisation to 6 months
| Intervention | thousand(RMB) (Median) |
|---|---|
| Neostigmine | 95.3 |
| Conservative Treatment | 102.3 |
Abdominal compartment syndrome is defined as a sustained IAP>20 mmHg (with or without an APP<60 mmHg) that is associated with new organ dysfunction/failure (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 2 |
| Conservative Treatment | 4 |
Incidence of organ failure from randomization to discharge or death, assessed up to 3 months (NCT02543658)
Timeframe: From randomization to discharge or death, assessed up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 12 |
| Conservative Treatment | 16 |
Due to that neostigmine has an inhibitory effect on the cardiovascular system, new-onset cardiovascular failure after grouping is considered as a possible adverse event related to neostigmine.Cardiovascular failure was defined as circulatory systolic blood pressure <90 mm Hg, despite adequate fluid resuscitation, or need for inotropic catecholamine support (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 8 |
| Conservative Treatment | 4 |
IAP rebound ≥ 5mmHg or increase ≥ 20mmHg within 1-7 days after grouping (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Neostigmine | 4 |
| Conservative Treatment | 8 |
From date of randomization to enteral nutrition, assessed up to 30 days (NCT02543658)
Timeframe: Start time of enteral nutrition after randomization, assessed up to 30 days
| Intervention | days (Median) |
|---|---|
| Neostigmine | 3 |
| Conservative Treatment | 4 |
Monitor the intra-abdominal pressure within 1 to 7 days after randomization, and calculate the percent change compared with that before randomization (NCT02543658)
Timeframe: From randomization to 7 days after treatment,Measured IAP every 6 hours
| Intervention | percent change of IAP (Median) | |
|---|---|---|
| percent change of IAP at 24 hours | percent change of IAP at 7 days | |
| Conservative Treatment | -5.4 | -20.0 |
| Neostigmine | -18.7 | -27.2 |
After randomization, the change of stool volume (ML) was calculated every 24 hours.For example, the amount of stool volume decreased or increased in 24 hours after grouping compared to before grouping. (NCT02543658)
Timeframe: From randomization to 7 days
| Intervention | ml/day (Median) | |
|---|---|---|
| The change of stool volume at 24 hours | The change of stool volume at 7th day | |
| Conservative Treatment | 60 | 370 |
| Neostigmine | 870 | 1025 |
2 trials available for neostigmine and Recrudescence
| Article | Year |
|---|---|
Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial.
Topics: Acute Disease; Aged; Cathartics; Colon; Colonic Pseudo-Obstruction; Colonoscopy; Decompression, Surg | 2006 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
Neostigmine for the treatment of acute colonic pseudo-obstruction.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colonic Ps | 1999 |
9 other studies available for neostigmine and Recrudescence
| Article | Year |
|---|---|
Recurrent Asystole After Neostigmine in a Heart Transplant Recipient With End-Stage Renal Disease.
Topics: Aged; Cholinesterase Inhibitors; Heart Arrest; Heart Transplantation; Humans; Kidney Failure, Chroni | 2017 |
[Clinical characteristics and follow-up management of 135 children with myasthenia gravis].
Topics: Adolescent; Age of Onset; Antibodies; Child; Child, Preschool; Female; Follow-Up Studies; Humans; In | 2011 |
Postoperative recurrent paralysis in an infant after mivacurium infusion.
Topics: Female; Humans; Infant; Infusions, Intravenous; Isoquinolines; Mivacurium; Muscle Contraction; Neost | 1994 |
[Diagnostic evaluation of tubeless methods in the study of external secretions of the pancreas].
Topics: Adult; Amino Acids; Amylases; Cholecystitis; Chronic Disease; Creatinine; Diagnosis, Differential; D | 1997 |
Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cholinesterase I | 2001 |
Absence of "recurarization" in patients with demonstrated prolonged neuromuscular block.
Topics: Adult; Cholinesterase Inhibitors; Edrophonium; Female; Humans; Male; Middle Aged; Neostigmine; Neuro | 1977 |
'Juvenile' myasthenia gravis in early infancy.
Topics: Age Factors; Blepharoptosis; Diagnostic Errors; Female; Humans; Infant; Myasthenia Gravis; Neostigmi | 1976 |
Beneficial use of an evocative test in chronic relapsing pancreatitis in children.
Topics: Abdomen; Adolescent; Amylases; Child; Child, Preschool; Chronic Disease; Female; Humans; Male; Morph | 1986 |
Thymoma, myasthenia gravis, erythroblastopenic anemia and systemic lupus erythematosus in one patient.
Topics: Ambenonium Chloride; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Bronchop | 1973 |